Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$15.81 USD
+0.16 (1.02%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $15.80 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Arcus Biosciences, Inc. [RCUS]
Reports for Purchase
Showing records 81 - 100 ( 122 total )
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Multiple Meaningful Moments Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ESMO 2020: Early Combination Data Showing Promise
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Randomized TIGIT/A2aR Data Ahead; Additional ESMO AB928 Data
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AACR II Takeaways: Promising AB928 Data in Colorectal Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
No Good Clues from Tiragolumab ASCO Presentation; AZN A2aR Update
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Gilead Buys In With Deal Approaching $2B in Value; Raising PT to $48
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CORRECTED: ASCO Virtual Meeting Abstract Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Raising PT to $40 on Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: May 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Three Assets Move to Randomized Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arcus Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Multiple Pipeline Readouts Ahead in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R